Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Imunon, Inc. - Common Stock (NQ: IMNN )

1.400 +0.100 (+7.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 175,996
Open 1.250
Bid (Size) 1.290 (3)
Ask (Size) 1.590 (1)
Prev. Close 1.300
Today's Range 1.250 - 1.550
52wk Range 1.060 - 1.990
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Imunon: Q1 Earnings Insights
 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 76 companies set new 52-week lows. 
Via Benzinga

Performance

YTD
-6.63%
-6.63%
1 Month
+3.70%
+3.70%
3 Month
+2.19%
+2.19%
6 Month
-0.71%
-0.71%
1 Year
-23.50%
-23.50%

More News

Read More
Imunon, Inc. - Common Stock Earnings Perspective: Return On Capital Employed
Via Benzinga
Imunon, Inc. - Common Stock Earnings Preview
Via Benzinga
Imunon, Inc. - Common Stock's Return On Capital Employed Overview
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
From Imunon, Inc.
Via GlobeNewswire
IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages
From Imunon, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022
From Imunon, Inc.
Via GlobeNewswire
IMUNON Announces Strategic Investment in Transomic Technologies
From Imunon, Inc.
Via GlobeNewswire
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update
From Imunon, Inc.
Via GlobeNewswire
IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System
From Imunon, Inc.
Via GlobeNewswire
Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022
From Imunon, Inc.
Via GlobeNewswire
Imunon Appoints James E. Dentzer to its Board of Directors
From Imunon, Inc.
Via GlobeNewswire
Imunon Reports Partial Results from Ongoing Non-human Primate Study
From Imunon, Inc.
Via GlobeNewswire
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
From Imunon, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.